SRINIVAS RANGU: Open Payments
NPI 1902963655 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$459 in 28 payments from 12 companies in 2025. Trend: 2023 $469 · 2024 $598 · 2025 $459
Food & beverage: $459
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 11 | $156 |
| Sumitomo Pharma America, Inc. | 6 | $100 |
| PFIZER INC. | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 1 | $25 |
| ABIOMED | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Amgen Inc. | 1 | $16 |
Products named: TRELEGY ELLIPTA, GEMTESA, LEQVIO, REXULTI, VYNDAQEL, Kerendia, JARDIANCE, ELIQUIS.
Industry payments across TX — which companies pay providers there.
